Unveiling novel prognostic biomarkers and therapeutic targets for HBV-associated hepatocellular carcinoma through integrated bioinformatic analysis

Xue Ren,Niaoniao Feng
DOI: https://doi.org/10.1097/md.0000000000040134
IF: 1.6
2024-10-30
Medicine
Abstract:Hepatocellular carcinoma (HCC) is responsible for approximately 90% of liver cancers and one of the leading causes of malignancy-related deaths in the world. [ 1 , 2 ] Over 90% of HCC cases are linked to known risk factors, including chronic viral hepatitis, alcohol consumption, and nonalcoholic fatty liver disease. [ 3 ] It has been reported that chronic hepatitis infections like hepatitis B (HBV) and hepatitis C virus infections are the primary cause of HCC in eastern Asia and also in sub-Saharan Africa. Of these, HBV is considered a recognized risk factor for HCC metastasis or recurrence. [ 4–6 ] The incidence of liver cancer cases in 2015 was 854,000, representing about 75% increase compared to 1990, while the number of deaths and Disability-Adjusted Life Years were 810,000 and 20,578,000, respectively. More importantly, over the next 2 decades, the prevalence of liver cancer is expected to rise. Epidemiological studies anticipate a 55% rise in incidence and a 56.4% increase in mortality attributable to liver cancer from 2020 to 2040. [ 7 ] Consequently, HCC continues to represent a significant challenge to global health infrastructure, both presently and in the future.
medicine, general & internal
What problem does this paper attempt to address?